Skip to main content
SpringerLink
Log in

An analysis of the involvement of monoaminergic mechanisms in the neuropsychotropic effects of neuroglutam

  • Experimental Articles
  • Published:
Neurochemical Journal Aims and scope Submit manuscript

Abstract

It is known that neuroglutam (at 26 mg/kg) potentiates stereotypy that is induced by the agonist of postsynaptic dopamine receptors apomorphine (1 mg/kg), and suppresses catalepsy that is induced by the blocker of postsynaptic dopamine receptors haloperidol (1 mg/kg), which points to its stimulatory influence on dopaminergic neurotransmission. Neuroglutam (26 mg/kg) does not affect the contents of noradrenaline and dopamine (DA) in homogenates of rat brain structures; however, it increases the concentration of the metabolites of dopamine 3,4-dioxyphenylacetic acid (DOPAC) in the frontal cortex and homovanillic acid (HVA) in the hippocampus, which points to its positive influence on the rate of DA utilization, and, in addition, an increase in indices that characterize the rate of DA turnover, viz., DOPAC/DA and HVA/DA in the striatum. We used the method of radioligand binding in vitro with [G-3H]-sulpiride to show that neuroglutam (10−10–10−4 M) does not directly interact with dopamine D2 receptors; however, during subchronic administration (5 days; a single daily dose of 26 mg/kg) neuroglutam promotes an increase in the density of D2 receptors in the prefrontal cortex, which points to its ability to modulate the expression of these receptors. The data from neurochemical and radioligand analysis suggest that both presynaptic (intensification of metabolic DA turnover) and postsynaptic (DA receptors) mechanisms of dopaminergic neurotransmission are involved in the neuropsychotropic action of neuroglutam. Neuroglutam did not influence the strength of hyperkinesia that was induced by the metabolic precursor of serotonin 5-hydroxytryptophan on the content of serotonin and its metabolites in rat-brain structures and did not alter the receptor binding of [G-3H]-ketanserin (an antagonist of 5-HT2A receptors) in the prefrontal cortex both under in vitro conditions and during subchronic administration ex vivo, which points to the absence of direct participation of the serotonergic system in the pharmacological action of the studied drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bagmetova, V.V., Chernysheva, Yu.V., Merkushenkova, O.V., Berestovitskaya, V.M., Vasil’eva, O.S., and Tyurenkov, I.N., Eksperimental’naya i Klinicheskaya Farmakologiya, 2013, vol. 76, no. 3, pp. 7–9.

    CAS  Google Scholar 

  2. Tyurenkov, I.N., Bagmetova, V.V., Chernysheva, Yu.V., and Yarkova, M.A., Eksperimental’naya i Klinicheskaya Farmakologiya, 2013, vol. 76, no. 11, pp. 7–12.

    CAS  Google Scholar 

  3. Mashkovskii, M.D., Seredenin, S.B., Al’tshuler, R., Vedernikov, A.A., Badyshtov, V.A., and Andreeva, N.I., Khimiko-Farmatsevticheskii Zhurnal, 1980, no. 5, pp. 7–9.

    Google Scholar 

  4. Novoselov, I.A., Cherepov, A.B., Raevskii, K.S., and Anokhin, K.V., Eksperimental’naya i Klinicheskaya Farmakologiya, 2002, vol. 65, no. 5, pp. 18–21.

    CAS  Google Scholar 

  5. Seredenin, S.B., Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2003, no. 12, pp. 35–38.

    Google Scholar 

  6. Alexander, R.C., Wright, R., and Freed, W., Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 1996, vol. 15, no. 5, pp. 484–490.

    Article  CAS  Google Scholar 

  7. Andreeva, N.I., Metodicheskie ukazaniya po izucheniyu antidepressantnoi aktivnosti farmakologicheskikh veshchestv. Rukovodstvo po eksperimental’nomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv (Methodical Guidance on Investigation of Antidepressant Activity of Pharmacological Substances. Manual on Experimental (Preclinical) Studies of New Pharmacological Substances), Khabriev, R.U., Ed., Moscow: OAO Izd. “Meditsina”, 2005, pp. 244–253.

  8. Voronina, T.A. and Guzevatykh, L.S., Metodicheskie rekomendatsii po izucheniyu anal’geticheskoi aktivnosti lekarstvennykh sredstv. Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv (Methodical Recommendations on Examination of Analgetic Activity of Medications. Manual on Performance of Preclinical Studies of Medications), Moscow: Grif i K, 2012, part 1.

    Google Scholar 

  9. Voronina, T.A., Val’dman, E.A., Nerobkova, L.N., and Kapitsa, I.G., Metodicheskie rekomendatsii po doklinicheskomu izucheniyu lekarstvennykh sredstv s protivoparkinsonicheskoi aktivnost’yu. Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv (Methodical Recommendations on Preclinical Studies of Medications with Antiparkinson Activity. Manual on Performance of Preclinical Studies of Medications), Moscow: Grif i K, 2012, part 1.

    Google Scholar 

  10. Matveeva, M.I., Shtemberg, A.S., Timoshenko, G.N., Krasavin, E.A., Narkevich, V.B., Klodt, P.M., Kudrin, V.S., and Bazyan, A.S., Neirokhimiya, 2013, vol. 30, no. 4, pp. 343–348.

    Google Scholar 

  11. Miroshnichenko, I.I., Kudrin, V.S., and Raevskii, K.S., Farmakol. i Toksikol, 1995, vol. 51, pp. 26–29.

    Google Scholar 

  12. Leysen, J.E. and Niemegeers, C.J., Mol. Pharmacol., 1982, vol. 21, no. 2, pp. 301–14.

    CAS  PubMed  Google Scholar 

  13. Sun, W., Ginovart, N., Ko, F., Seeman, P., and Kapur, S., Mol. Pharmacol., 2003, vol. 63, no. 2, pp. 456–462.

    Article  CAS  PubMed  Google Scholar 

  14. Yakimovskii, A.F., Red’ka, Yu.A., and Yakubenko, A.L., Zhurn. Vysshei Nervnoi Deyatel’nosti, 2010, vol. 60, no. 1, pp. 90–197.

    CAS  Google Scholar 

  15. Paquet, M. and Smith, Y., J. Neurosci., 2003, vol. 23, no. 20, pp. 7659–7669.

    CAS  PubMed  Google Scholar 

  16. Espinoza, S., Salahpour, A., Masri, B., Sotnikova, T.D., Messa, M., Barak, L.S., Caron, M.G., and Gainetdinov, R.R., Molecular Pharmacology, 2011, vol. 80, no. 3, pp. 416–425.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Revel, F.G., Moreau, J.-L., Gainetdinov, R.R., Bradaia, A., Sotnikova, T.D., Mory, R., Durkin, S., Zbinden, K.G., Norcross, R., Meyer, C.A., Metzler, V., Chaboz, S., Ozmen, L., Trube, G., Pouzet, B., Bettler, B., Caron, M.G., Wettstein, J.G., and Hoener, M.C., PNAS, vol. 108, no. 20, pp. 8485–8490.

  18. Xie, Z. and Miller, G.M., Journal of Pharmacology and Experimental Therapeutics, 2007, vol. 321, no. 1, pp. 128–136.

    Article  CAS  PubMed  Google Scholar 

  19. Kaluev, A.V., Neironauki, 2006, no. 2(4), pp. 29–41.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Biopharmacy, Doctor Improvement Faculty, Volgograd State Medical University, Volgograd, Russia

    I. N. Tyurenkov, V. V. Bagmetova, O. V. Merkushenkova & Yu. V. Markina

  2. Zakusov Institute of Pharmacology, Moscow, Russia

    P. M. Klodt, V. B. Narkevich, V. S. Kudrin, E. A. Kondrakhin, E. V. Vasil’eva & G. I. Kovalev

Authors
  1. I. N. Tyurenkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. V. Bagmetova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. V. Merkushenkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu. V. Markina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. M. Klodt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. B. Narkevich
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. S. Kudrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. A. Kondrakhin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E. V. Vasil’eva
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. I. Kovalev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. V. Bagmetova.

Additional information

Original Russian Text © I.N. Tyurenkov, V.V. Bagmetova, O.V. Merkushenkova, Yu.V. Markina, P.M. Klodt, V.B. Narkevich, V.S. Kudrin, E.A. Kondrakhin, E.V. Vasil’eva, G.I. Kovalev, 2015, published in Neirokhimiya, 2015, Vol. 32, No. 1, pp. 27–36.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tyurenkov, I.N., Bagmetova, V.V., Merkushenkova, O.V. et al. An analysis of the involvement of monoaminergic mechanisms in the neuropsychotropic effects of neuroglutam. Neurochem. J. 9, 20–28 (2015). https://doi.org/10.1134/S1819712415010122

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1819712415010122

Keywords

Search

Navigation